Good News for the Bubble Baby Disease Treatment Backed by Millions from California Taxpayers
By David Jensen,
The California Stem Cell Report
| 02. 15. 2022
Photo: CIRM
Twenty children seeking treatment for a rare affliction called the “bubble baby disease” today have some big-time, good news concerning a life-saving genetic therapy that they were once denied as the result of a tangled affair involving private profit and the public funding of cutting-edge scientific research.
After being halted nearly two years ago, a California state-financed clinical trial that can help the children is now solidly on its way to a new beginning at UCLA. Treatments of the children could begin as early as June.
The California stem cell agency is expected to provide $5.8 million to resume the trial at UCLA. Millions more are likely to be forthcoming from the agency, officially known as the California Institute for Regenerative Medicine (CIRM).
Despite the success of the trial over the last several years -- “100 percent overall survival” of 50 patients -- it was abandoned in 2020 by Orchard Therapeutics, PLC. Instead, Orchard turned towards research that it deemed would be more profitable. At that time, Orchard had exclusive rights to the therapy, which was...
Related Articles
By Alondra Nelson, Science | 09.11.2025
In the United States, the summer of 2025 will be remembered as artificial intelligence’s (AI’s) cruel summer—a season when the unheeded risks and dangers of AI became undeniably clear. Recent months have made visible the stakes of the unchecked use...
By Emma McDonald Kennedy
| 09.25.2025
In the leadup to the 2024 election, Donald Trump repeatedly promised to make IVF more accessible. He made the commitment central to his campaign, even referring to himself as the “father of IVF.” In his first month in office, Trump issued an executive order promising to expand IVF access. The order set a 90-day deadline for policy recommendations for “lowering costs and reducing barriers to IVF,” although it didn’t make any substantive reproductive healthcare policy changes.
The response to the...
Sir Francis Galton, 1890s, by Eveleen Myers (née Tennant)
npg.org
Public Domain via Wikipedia
As has been discussed in recent issues of Biopolitical Times (1, 2), there are, increasingly, companies that claim to be selling parents better babies by selecting the “best” embryos. These services don’t come cheap – think $50,000, or even more, for embryo testing, plus perhaps as much again for IVF and concomitant services. To most of us, that is extremely expensive...
By Johana Bhuiyan, The Guardian | 09.23.2025
In March 2021, a 25-year-old US citizen was traveling through Chicago’s Midway airport when they were stopped by US border patrol agents. Though charged with no crime, the 25-year-old was subjected to a cheek swab to collect their DNA, which...
